血管内修复对破裂性胸主动脉瘤治疗策略及结局的影响
该研究基于美国全国住院患者样本,分析1993至2012年破裂性胸主动脉瘤的治疗趋势。结果显示TEVAR使用率从2003-2004年的2%升至2011-2012年的43%,开放修复比例下降,手术修复比例在80岁以上人群增加7.5倍。TEVAR引入后手术死亡率从36%降至27%,总体死亡率从55%降至42%,调整后开放修复死亡风险为TEVAR的2倍。
要点
- TEVAR已取代开放修复成为破裂性胸主动脉瘤的主要手术治疗方式。
- TEVAR引入后手术修复比例增加,尤其80岁以上人群增加7.5倍。
- 调整后开放修复死亡风险为TEVAR的2.0倍(95%CI 1.7-2.5)。
核心结论
- TEVAR已取代开放修复成为破裂性胸主动脉瘤的主要手术治疗方式。
- 血管内治疗的引入扩大了手术治疗的适用人群,尤其是老年患者。
- TEVAR引入后破裂性胸主动脉瘤入院后总体死亡率下降,归因于手术死亡率改善及手术修复比例增加。
研究设计与样本
- 基于美国全国住院患者样本(National Inpatient Sample)的回顾性分析。
- 纳入1993至2012年因破裂性胸主动脉瘤入院患者共12,399例。
- 按治疗方式分为TEVAR组1622例(13%)、开放修复组2808例(23%)和非手术治疗组7969例(64%)。
- 主要结局为治疗趋势随时间变化及院内死亡,次要结局为围手术期并发症和住院时长。
- 趋势分析采用Cochran-Armitage趋势检验,调整死亡风险采用多变量逻辑回归分析。
主要发现
- TEVAR使用率从2003-2004年占总入院的2%升至2011-2012年的43%(P < .001)。
- 同期开放修复比例从29%降至12%(P < .001),非手术治疗比例从69%降至45%(P < .001)。
- 自1993-1994年以来所有年龄组手术修复比例均增加(P < .001),80岁人群增加7.5倍最为显著。
- TEVAR引入后手术死亡率从2003-2004年的36%降至2011-2012年的27%(P < .001),非手术治疗死亡率在63%至60%间保持稳定(P = .167)。
- 破裂性胸主动脉瘤入院后总体死亡率从55%降至42%(P < .001);自2005年以来开放修复死亡率为33%,TEVAR为22%(P < .001)。
关键数值与推荐
- 调整分析中开放修复死亡风险为TEVAR的2.0倍( odds ratio 2.0;95%CI 1.7-2.5)。
临床怎么用
- 对于破裂性胸主动脉瘤,TEVAR应作为优先考虑的手术治疗方式。
- TEVAR的引入可扩大老年患者接受手术治疗的适用人群。
- 治疗决策中需权衡开放修复较高的调整死亡风险(为TEVAR的2倍)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Thoracic endovascular aortic repair (TEVAR) has become an alternative to open repair for the treatment of ruptured thoracic aortic aneurysms (rTAAs). The aim of this study was to assess national trends in the use of TEVAR for the treatment of rTAA and to determine its impact on perioperative outcomes. METHODS: Patients admitted with an rTAA between 1993 and 2012 were identified from the National Inpatient Sample. Patients were grouped in accordance with their treatment: TEVAR, open repair, or nonoperative treatment. The primary outcomes were treatment trends over time and in-hospital death. Secondary outcomes included perioperative complications and length of stay. Trend analyses were performed using the Cochran-Armitage test for trend, and adjusted mortality risks were established using multivariable logistic regression analysis. RESULTS: A total of 12,399 patients were included, with 1622 (13%) undergoing TEVAR, 2808 (23%) undergoing open repair, and 7969 (64%) not undergoing surgical treatment. TEVAR has been increasingly used from 2% of total admissions in 2003-2004 to 43% in 2011-2012 (P < .001). Concurrently, there was a decline in the proportion of patients undergoing open repair (29% to 12%; P < .001) and nonoperative treatment (69% to 45%; P < .001). The proportion of patients undergoing surgical repair has increased for all age groups since 1993-1994 (P < .001 for all) but was most pronounced among those aged 80 years with a 7.5-fold increase. After TEVAR was introduced, procedural mortality decreased from 36% in 2003-2004 to 27% in 2011-2012 (P < .001); mortality among those undergoing nonoperative treatment remained stable between 63% and 60% (P = .167). Overall mortality after rTAA admission decreased from 55% to 42% (P < .001). Since 2005, mortality for open repair was 33% and 22% for TEVAR (P < .001). In adjusted analysis, open repair was associated with a twofold higher mortality than TEVAR (odds ratio, 2.0; 95% confidence interval, 1.7-2.5). CONCLUSIONS: TEVAR has replaced open repair as primary surgical treatment for rTAA. The introduction of endovascular treatment appears to have broadened the eligibility of patients for surgical treatment, particularly among the elderly. Mortality after rTAA admission has declined since the introduction of TEVAR, which is the result of improved operative mortality as well as the increased proportion of patients undergoing surgical repair.
引用
- Ultee KHJ, Zettervall SL, Soden PA, et al. The impact of endovascular repair on management and outcome of ruptured thoracic aortic aneurysms. J Vasc Surg. 2017. PMID: 28366304. doi:10.1016/j.jvs.2017.01.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。